Skip to content Skip to sidebar Skip to footer
Subscribe Now
Viewpoints_Thierry Abribat
VIEWPOINTS

PharmaShots Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on AZP-3601 for Hypoparathyroidism

In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer of Amolyt Pharma share his views on the clinical profile of AZP-3601. He also shed light on how it differs from other treatments in development for hypoparathyroidism.Shots:Amolyt Pharma presented positive data from the single ascending dose (SAD) portion of its Ph1 study evaluating AZP-3601…
May 10, 20210Comments

Read more

Viewpoints_Sven Sjovall & Dr. Mark Watt
VIEWPOINTS

PharmaShots Interview: J&J’s Sven Sjovall & Dr. Mark Watt Share Insight on Nicorette’s Latest Digital Smoking Cessation Offering

In an interview with PharmaShots, Johnson & Johnson's Sven Sjovall, Sr Director, R&D Site Lead and Global Smoking Cessation, and Dr. Mark Watt, Senior Director Medical Affairs and Clinical Research at Johnson & Johnson share their views on Nicorette's latest digital smoking cessation offering and the science behind the QuickMist SmartTrack. They also shed some light on…
May 5, 20210Comments

Read more

Viewpoints_Dr. Drew Falconer
VIEWPOINTS

PharmaShots Interview: Dr. Drew Falconer Shares Insights on the Abbott’s NeuroSphere Virtual Clinic

In an interview with PharmaShots, Dr. Drew Falconer, Neurologist and Director at Inova Parkinson's and Movement Disorders Center in Fairfax, Va. shares insights on the first neurostimulation technology in the US that allows patients to receive treatment from the doctor without leaving home.Shots:Abbott launches NeuroSphere Virtual Clinic that allows patients to communicate with their physicians,…
May 3, 20210Comments

Read more

Viewpoints_Dr. Robert Koenekoop
VIEWPOINTS

PharmaShots Interview: Dr. Robert Koenekoop Shares Insights on Stellar Study Evaluating ProQR’s QR-421a

In an interview with PharmaShots, Dr. Robert Koenekoop, MD, PhD, Professor of Pediatric Surgery, Human Genetics and Adult Ophthalmology at McGill University's Montreal Children's Hospital shared his views on the clinical data of the trial and shed light on how RNA therapies work in eye disorders?Shots:QR-421a demonstrated a concordant benefit in multiple measures of vision…
May 3, 20210Comments

Read more

Thoughtspot_Sunaina Anand
THOUGHTSPOT

Adjunctive Nutraceutical Therapies Supporting Immunity in COVID-19

Nutraceuticals such as active phytochemicals, functional foods, and dietary supplements have medicinal properties and a variety of health benefits. The Indian subcontinent has been renowned for a home to various medicinal plant species because of climate conditions. These medicinal plant species have a novel role in managing multiple illnesses, including viral respiratory diseases, through immune…
April 28, 20210Comments

Read more

Viewpoints_Emmanuel Dulac
VIEWPOINTS

PharmaShots Interview: Zealand Pharma’s Emmanuel Dulac Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes

In an interview with PharmaShots, Emmanuel Dulac, Pharm.D., Ph.D., President and CEO of Zealand Pharma shares insight on the US FDA's approval of Zegalogue and its availability in both an auto-injector and a prefilled syringe in June 2021. He also highlighted the importance of approval for the company and patients with hypoglycemia.  Shots:The approval is based…
April 28, 20210Comments

Read more

Viewpoints_Dr. Lara S. Sullivan and Dr. Ronald Herbst
VIEWPOINTS

PharmaShots Interview: Pyxis Oncology’s Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Funding to Advance their Portfolio

In an interview with PharmaShots, Dr. Lara S. Sullivan, Chief Executive Officer, and Dr. Ronald Herbst, Chief Scientific Officer of Pyxis Oncology share insight on the importance of Series B funding and shed light on the company's strategy and near-term goals.Shots:Pyxis Oncology reported that it raised $152M in a series B on the heels of…
April 26, 20210Comments

Read more

Viewpoints_Dr. Saoirse O'Sullivan
VIEWPOINTS

PharmaShots Interview: Artelo Bio’s Dr. Saoirse O’Sullivan Shares Insights on Synthetic Cannabinoid for Cancer Anorexia

In an interview with PharmaShots, Dr. Saoirse O'Sullivan, Ph.D., Scientific Advisor to Artelo Bio shares insights on new cannabinoids, their relevancy, and the other opportunities that can arise from modulating the ECS.Shots:The endocannabinoid system is a network of neurotransmitters and receptors throughout the body that can have a significant impact on improving human health when affected…
April 23, 20210Comments

Read more